US OptionsDetailed Quotes
RVPH241018P2500
- 1.30
- 0.000.00%
15min DelayClose Oct 4 16:00 ET
0.00High0.00Low
1.30Open1.30Pre Close0 Volume4 Open Interest2.50Strike Price0.00Turnover293.68%IV4.00%PremiumOct 18, 2024Expiry Date1.25Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.8238Delta0.3672Gamma0.96Leverage Ratio-0.0064Theta-0.0007Rho-0.79Eff Leverage0.0006Vega
Reviva Pharmaceuticals Stock Discussion
Sign in to post a comment
$Reviva Pharmaceuticals (RVPH.US)$ primed for a big move soon
2
$Reviva Pharmaceuticals (RVPH.US)$
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia –
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOB...
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia –
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOB...
$Reviva Pharmaceuticals (RVPH.US)$
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Closing of $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
4
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Pharmaceuticals Holdings, Inc. -Topline Data From 1-Year Open-Label Extension (Ole) Trial Expected in Q4 2024
$Reviva Pharmaceuticals (RVPH.US)$ Reviva Announces Alignment With FDA On Brilaroxazine Clinical Trials For NDA In Schizophrenia; FDA Accepts 4-Week RECOVER-2 Study
2
$Reviva Pharmaceuticals (RVPH.US)$ H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) today and set a price target of $20.00.
1
No comment yet
Lnova : anything in particular that makes you think so?
Clintzilla OP Lnova : just saw this, ill come back to it.. Pipeline i have something wrote down somewhere.. float is bigger than usual but i played this like 3-9 last time